Annual EBITDA
-$65.25 M
-$11.33 M-21.01%
December 31, 2023
Summary
- As of February 7, 2025, LYRA annual EBITDA is -$65.25 million, with the most recent change of -$11.33 million (-21.01%) on December 31, 2023.
- During the last 3 years, LYRA annual EBITDA has fallen by -$43.14 million (-195.06%).
- LYRA annual EBITDA is now -809.15% below its all-time high of -$7.18 million, reached on December 31, 2018.
Performance
LYRA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$9.60 M
+$8.06 M+45.65%
September 30, 2024
Summary
- As of February 7, 2025, LYRA quarterly EBITDA is -$9.60 million, with the most recent change of +$8.06 million (+45.65%) on September 30, 2024.
- Over the past year, LYRA quarterly EBITDA has increased by +$7.23 million (+42.95%).
- LYRA quarterly EBITDA is now -165.46% below its all-time high of -$3.62 million, reached on March 31, 2019.
Performance
LYRA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$67.04 M
+$7.23 M+9.73%
September 30, 2024
Summary
- As of February 7, 2025, LYRA TTM EBITDA is -$67.04 million, with the most recent change of +$7.23 million (+9.73%) on September 30, 2024.
- Over the past year, LYRA TTM EBITDA has dropped by -$4.66 million (-7.46%).
- LYRA TTM EBITDA is now -1753.95% below its all-time high of -$3.62 million, reached on March 31, 2019.
Performance
LYRA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
LYRA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.0% | +43.0% | -7.5% |
| 3 y3 years | -195.1% | +43.0% | -7.5% |
| 5 y5 years | -809.1% | +43.0% | -7.5% |
LYRA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -53.1% | at low | at high | +59.0% | -57.3% | +9.7% |
| 5 y | 5-year | -295.6% | at low | -126.4% | +59.0% | -306.5% | +9.7% |
| alltime | all time | -809.1% | at low | -165.5% | +59.0% | -1754.0% | +9.7% |
Lyra Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.60 M(-45.6%) | -$67.04 M(-9.7%) |
| Jun 2024 | - | -$17.66 M(-24.5%) | -$74.27 M(+3.8%) |
| Mar 2024 | - | -$23.39 M(+42.7%) | -$71.52 M(+9.8%) |
| Dec 2023 | -$65.25 M(+21.0%) | -$16.39 M(-2.6%) | -$65.16 M(+4.4%) |
| Sep 2023 | - | -$16.83 M(+12.8%) | -$62.38 M(+3.8%) |
| Jun 2023 | - | -$14.91 M(-12.4%) | -$60.10 M(+1.3%) |
| Mar 2023 | - | -$17.03 M(+25.1%) | -$59.31 M(+10.0%) |
| Dec 2022 | -$53.92 M(+26.5%) | -$13.62 M(-6.4%) | -$53.92 M(+0.5%) |
| Sep 2022 | - | -$14.55 M(+3.1%) | -$53.67 M(+7.7%) |
| Jun 2022 | - | -$14.11 M(+21.2%) | -$49.85 M(+7.2%) |
| Mar 2022 | - | -$11.64 M(-12.8%) | -$46.50 M(+9.1%) |
| Dec 2021 | -$42.61 M | -$13.36 M(+24.5%) | -$42.61 M(+17.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$10.73 M(-0.3%) | -$36.27 M(+13.8%) |
| Jun 2021 | - | -$10.76 M(+38.7%) | -$31.86 M(+24.3%) |
| Mar 2021 | - | -$7.76 M(+10.7%) | -$25.64 M(+15.9%) |
| Dec 2020 | -$22.11 M(+34.1%) | -$7.01 M(+10.8%) | -$22.11 M(+13.5%) |
| Sep 2020 | - | -$6.33 M(+39.7%) | -$19.48 M(+12.1%) |
| Jun 2020 | - | -$4.53 M(+6.9%) | -$17.37 M(+1.5%) |
| Mar 2020 | - | -$4.24 M(-3.2%) | -$17.12 M(+3.8%) |
| Dec 2019 | -$16.49 M(+129.8%) | -$4.38 M(+3.8%) | -$16.49 M(+36.2%) |
| Sep 2019 | - | -$4.22 M(-1.3%) | -$12.11 M(+53.5%) |
| Jun 2019 | - | -$4.28 M(+18.2%) | -$7.89 M(+118.2%) |
| Mar 2019 | - | -$3.62 M | -$3.62 M |
| Dec 2018 | -$7.18 M | - | - |
FAQ
- What is Lyra Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Lyra Therapeutics?
- What is Lyra Therapeutics annual EBITDA year-on-year change?
- What is Lyra Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Lyra Therapeutics?
- What is Lyra Therapeutics quarterly EBITDA year-on-year change?
- What is Lyra Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Lyra Therapeutics?
- What is Lyra Therapeutics TTM EBITDA year-on-year change?
What is Lyra Therapeutics annual EBITDA?
The current annual EBITDA of LYRA is -$65.25 M
What is the all time high annual EBITDA for Lyra Therapeutics?
Lyra Therapeutics all-time high annual EBITDA is -$7.18 M
What is Lyra Therapeutics annual EBITDA year-on-year change?
Over the past year, LYRA annual EBITDA has changed by -$11.33 M (-21.01%)
What is Lyra Therapeutics quarterly EBITDA?
The current quarterly EBITDA of LYRA is -$9.60 M
What is the all time high quarterly EBITDA for Lyra Therapeutics?
Lyra Therapeutics all-time high quarterly EBITDA is -$3.62 M
What is Lyra Therapeutics quarterly EBITDA year-on-year change?
Over the past year, LYRA quarterly EBITDA has changed by +$7.23 M (+42.95%)
What is Lyra Therapeutics TTM EBITDA?
The current TTM EBITDA of LYRA is -$67.04 M
What is the all time high TTM EBITDA for Lyra Therapeutics?
Lyra Therapeutics all-time high TTM EBITDA is -$3.62 M
What is Lyra Therapeutics TTM EBITDA year-on-year change?
Over the past year, LYRA TTM EBITDA has changed by -$4.66 M (-7.46%)